Citigroup Inc. lowered its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON – Free Report) by 15.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 76,955 shares of the biotechnology company’s stock after selling 13,943 shares during the period. Citigroup Inc. owned about 0.10% of Axon Enterprise worth $17,303,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also modified their holdings of the stock. Kovack Advisors Inc. increased its stake in shares of Axon Enterprise by 1.2% during the first quarter. Kovack Advisors Inc. now owns 3,997 shares of the biotechnology company’s stock worth $899,000 after purchasing an additional 47 shares in the last quarter. AE Wealth Management LLC grew its stake in Axon Enterprise by 3.9% during the 1st quarter. AE Wealth Management LLC now owns 1,418 shares of the biotechnology company’s stock valued at $319,000 after acquiring an additional 53 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Axon Enterprise by 1.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,340 shares of the biotechnology company’s stock valued at $720,000 after acquiring an additional 58 shares in the last quarter. Oak Ridge Investments LLC grew its stake in Axon Enterprise by 0.6% during the 1st quarter. Oak Ridge Investments LLC now owns 10,484 shares of the biotechnology company’s stock valued at $2,357,000 after acquiring an additional 61 shares in the last quarter. Finally, Advisor Partners II LLC grew its stake in Axon Enterprise by 2.6% during the 4th quarter. Advisor Partners II LLC now owns 2,632 shares of the biotechnology company’s stock valued at $437,000 after acquiring an additional 66 shares in the last quarter. Hedge funds and other institutional investors own 76.52% of the company’s stock.
Insiders Place Their Bets
In other Axon Enterprise news, insider Jeffrey C. Kunins sold 22,900 shares of the stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $193.12, for a total transaction of $4,422,448.00. Following the sale, the insider now directly owns 241,076 shares in the company, valued at approximately $46,556,597.12. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, insider Jeffrey C. Kunins sold 22,900 shares of the firm’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $193.12, for a total value of $4,422,448.00. Following the sale, the insider now directly owns 241,076 shares in the company, valued at approximately $46,556,597.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, President Joshua Isner sold 26,883 shares of the firm’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $193.10, for a total transaction of $5,191,107.30. Following the completion of the sale, the president now owns 290,965 shares in the company, valued at $56,185,341.50. The disclosure for this sale can be found here. Insiders have sold a total of 51,265 shares of company stock worth $9,905,331 in the last ninety days. 6.10% of the stock is owned by corporate insiders.
Analyst Ratings Changes
AXON has been the subject of several research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $240.00 price objective on shares of Axon Enterprise in a research note on Wednesday, August 9th. JPMorgan Chase & Co. raised shares of Axon Enterprise from a “neutral” rating to an “overweight” rating and set a $236.00 price target for the company in a research note on Thursday, May 11th. Robert W. Baird increased their price target on shares of Axon Enterprise from $237.00 to $240.00 in a research note on Thursday, May 11th. Barclays dropped their price target on shares of Axon Enterprise from $256.00 to $239.00 and set an “overweight” rating for the company in a research note on Wednesday, August 9th. Finally, StockNews.com assumed coverage on shares of Axon Enterprise in a research note on Wednesday, August 23rd. They issued a “hold” rating for the company. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $244.73.
View Our Latest Stock Analysis on Axon Enterprise
Axon Enterprise Price Performance
Axon Enterprise stock opened at $200.71 on Tuesday. The firm has a market cap of $15.01 billion, a PE ratio of 149.78 and a beta of 0.88. Axon Enterprise, Inc. has a 52-week low of $109.31 and a 52-week high of $229.95. The company has a quick ratio of 2.98, a current ratio of 3.38 and a debt-to-equity ratio of 0.47. The company’s 50 day moving average is $192.20 and its two-hundred day moving average is $203.64.
Axon Enterprise (NASDAQ:AXON – Get Free Report) last released its earnings results on Tuesday, August 8th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.47. The company had revenue of $374.61 million for the quarter, compared to analyst estimates of $347.53 million. Axon Enterprise had a net margin of 7.24% and a return on equity of 10.88%. On average, research analysts expect that Axon Enterprise, Inc. will post 1.66 EPS for the current fiscal year.
Axon Enterprise Profile
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
See Also
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON – Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Axon Enterprise, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Axon Enterprise wasn’t on the list.
While Axon Enterprise currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
